• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体及其对全球严重急性呼吸综合征冠状病毒2/冠状病毒病(COVID-19)疫苗接种计划的影响
Vaccines (Basel). 2021 Mar 11;9(3):243. doi: 10.3390/vaccines9030243.
2
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.关注的新冠病毒变异株的生物学功能及临床意义
Front Med (Lausanne). 2022 May 20;9:849217. doi: 10.3389/fmed.2022.849217. eCollection 2022.
3
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
4
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
5
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.SARS-CoV-2 刺突 RBD 中的 V367F 突变增强了与人类 ACE2 受体的结合亲和力,从而提高了病毒的感染性。
J Virol. 2021 Jul 26;95(16):e0061721. doi: 10.1128/JVI.00617-21.
6
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.靶向刺突蛋白不同表位的抗体对新型 SARS-CoV-2 关切变异株的交叉中和作用
mBio. 2021 Dec 21;12(6):e0297521. doi: 10.1128/mBio.02975-21. Epub 2021 Nov 16.
7
SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.SARS-CoV-2 变体、RBD 突变、结合亲和力和抗体逃逸。
Int J Mol Sci. 2021 Nov 9;22(22):12114. doi: 10.3390/ijms222212114.
8
Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.源自古老动物的单域抗体作为针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和其他冠状病毒的广泛中和剂。
Biomed Eng Adv. 2022 Dec;4:100054. doi: 10.1016/j.bea.2022.100054. Epub 2022 Sep 18.
9
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
10
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.受体结合域和 N 端结构域中和抗体的联合应用限制了 SARS-CoV-2 刺突蛋白中和逃逸突变体的产生。
mBio. 2021 Oct 26;12(5):e0247321. doi: 10.1128/mBio.02473-21. Epub 2021 Oct 5.

引用本文的文献

1
SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations.严重急性呼吸综合征冠状病毒2感染与抗病毒策略:进展与局限
Viruses. 2025 Jul 30;17(8):1064. doi: 10.3390/v17081064.
2
Exploring the diverse factors influencing healthcare utilization during the COVID-19 crisis.探索新冠疫情危机期间影响医疗保健利用的各种因素。
Front Public Health. 2025 May 16;13:1512735. doi: 10.3389/fpubh.2025.1512735. eCollection 2025.
3
Preeclamptic Placental CD19+ B Cells Are Causal to Hypertension During Pregnancy.子痫前期胎盘CD19 + B细胞是孕期高血压的病因。
Hypertension. 2025 May;82(5):894-903. doi: 10.1161/HYPERTENSIONAHA.124.24552. Epub 2025 Apr 2.
4
Validation and implementation of TaqMAMA RT-PCR for SARS-CoV-2 variant surveillance: experience from a high-volume setting.用于SARS-CoV-2变异株监测的TaqMAMA RT-PCR的验证与实施:来自高样本量环境的经验
BMC Infect Dis. 2025 Feb 24;25(1):256. doi: 10.1186/s12879-025-10645-8.
5
Comparative Evolutionary Epidemiology of SARS-CoV-2 Delta and Omicron Variants in Kuwait.科威特SARS-CoV-2德尔塔和奥密克戎变异株的比较进化流行病学
Viruses. 2024 Nov 30;16(12):1872. doi: 10.3390/v16121872.
6
Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023.2022 年至 2023 年期间,在中国广东省观察到 SARS-CoV-2 奥密克戎 BA.5 和 XBB.1.9 流行后的免疫逃逸现象。
Virol J. 2024 Nov 20;21(1):298. doi: 10.1186/s12985-024-02573-x.
7
Current Updates on Variants of SARS-CoV- 2: Systematic Review.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株的最新情况:系统评价
Health Sci Rep. 2024 Nov 4;7(11):e70166. doi: 10.1002/hsr2.70166. eCollection 2024 Nov.
8
A Regional-Scale Assessment-Based SARS-CoV-2 Variants Control Modeling with Implications for Infection Risk Characterization.基于区域尺度评估的SARS-CoV-2变体控制模型及其对感染风险特征描述的意义
Infect Drug Resist. 2024 Oct 31;17:4791-4805. doi: 10.2147/IDR.S480086. eCollection 2024.
9
Obesity as a Risk Factor for the Severity of COVID-19 in Pediatric Patients: Possible Mechanisms-A Narrative Review.肥胖作为儿童 COVID-19 严重程度的风险因素:可能机制——一项叙述性综述
Children (Basel). 2024 Sep 30;11(10):1203. doi: 10.3390/children11101203.
10
Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.设计 SARS-CoV-2 刺突蛋白保守表位肽作为广谱 COVID-19 疫苗。
Appl Microbiol Biotechnol. 2024 Oct 16;108(1):486. doi: 10.1007/s00253-024-13331-y.

本文引用的文献

1
Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda.乌干达出现并传播了一种具有刺突蛋白改变的 SARS-CoV-2 谱系 A 变种(A.23.1)。
Nat Microbiol. 2021 Aug;6(8):1094-1101. doi: 10.1038/s41564-021-00933-9. Epub 2021 Jun 23.
2
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
3
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
4
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
5
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
6
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
7
Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19.与 COVID-19 中 SARS-CoV-2 病毒亚群相关的住院和死亡。
Sci Rep. 2021 Feb 26;11(1):4802. doi: 10.1038/s41598-021-82850-9.
8
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.全面绘制影响多克隆人血浆抗体识别的 SARS-CoV-2 受体结合域突变图谱。
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8.
9
Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people.新型SARS-CoV-2变体B.1.1.7对儿童和年轻人的影响。
Lancet Child Adolesc Health. 2021 Apr;5(4):e9-e10. doi: 10.1016/S2352-4642(21)00030-4. Epub 2021 Feb 10.
10
Emergence of a Novel SARS-CoV-2 Variant in Southern California.新型 SARS-CoV-2 变异株在南加州出现。
JAMA. 2021 Apr 6;325(13):1324-1326. doi: 10.1001/jama.2021.1612.

新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体及其对全球严重急性呼吸综合征冠状病毒2/冠状病毒病(COVID-19)疫苗接种计划的影响

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.

作者信息

Gómez Carmen Elena, Perdiguero Beatriz, Esteban Mariano

机构信息

Centro Nacional de Biotecnología, Department of Molecular and Cellular Biology, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain.

出版信息

Vaccines (Basel). 2021 Mar 11;9(3):243. doi: 10.3390/vaccines9030243.

DOI:10.3390/vaccines9030243
PMID:33799505
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7999234/
Abstract

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants in different continents is causing a major concern in human global health. These variants have in common a higher transmissibility, becoming dominant within populations in a short time, and an accumulation of a high number of mutations in the spike (S) protein, especially within the amino terminal domain (NTD) and the receptor binding domain (RBD). These mutations have direct implications on virus infection rates through higher affinity of S RBD for the cellular angiotensin-converting enzyme-2 (ACE-2) receptor. There are also signs of enhanced virulence, re-infection frequency, and increased resistance to the action of monoclonal and polyclonal antibodies from convalescence sera and in vaccinated individuals in regions where the variants spread dominantly. In this review, we describe the different SARS-CoV-2 variants that have thus far been identified in various parts of the world with mutational changes and biological properties as well as their impact in medical countermeasures and human health.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变种在不同大洲的出现,引发了全球人类健康领域的重大担忧。这些变种的共同特点是具有更高的传播性,能在短时间内在人群中占据主导地位,并且其刺突(S)蛋白,尤其是氨基末端结构域(NTD)和受体结合结构域(RBD)积累了大量突变。这些突变通过S RBD对细胞血管紧张素转换酶2(ACE-2)受体的更高亲和力,直接影响病毒感染率。在变种占主导传播的地区,还出现了毒力增强、再感染频率增加以及对康复血清中和接种疫苗个体的单克隆和多克隆抗体作用的抗性增加的迹象。在这篇综述中,我们描述了迄今为止在世界不同地区发现的具有突变变化和生物学特性的不同SARS-CoV-2变种,以及它们对医学应对措施和人类健康的影响。